Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ironwood Pharmaceuticals Inc IRWD

Healthcare Biotechnology
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of... see more

Recent & Breaking News (NDAQ:IRWD)

Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Health Care Conference

Business Wire May 7, 2013

Free Research Reports on HSTM, IIVI, IRWD and SCMP Issued by the Bedford Report

Marketwired April 25, 2013

Ironwood Pharmaceuticals Provides First Quarter 2013 Investor Update

Business Wire April 23, 2013

Ironwood Pharmaceuticals to Host First Quarter 2013 Investor Update Call

Business Wire April 2, 2013

Prescription for Success: Commercialization Efforts, Acquisitions and Enhanced Patent Protection - Research Report on PAREXEL International, Ironwood Pharmaceuticals, Opko Health, Amarin Corporation, Progenics Pharmaceuticals

PR Newswire March 19, 2013

Pipeline Initiatives, Partnerships to Drive Growth - Research Report on Pfizer, Theravance, ISIS Pharmaceuticals, Infinity Pharmaceuticals and Ironwood

PR Newswire March 7, 2013

Ironwood Pharmaceuticals to Present at Cowen and Company 33rd Annual Health Care Conference

Business Wire February 25, 2013

Ironwood Pharmaceuticals Promotes Dr. Mark Currie to Senior Vice President, Chief Scientific Officer, and President of R&D

Business Wire February 11, 2013

Free Research Reports on CLRO, CLSN, GSX and IRWD Issued by the Bedford Report

Marketwired January 17, 2013

Ironwood Pharmaceuticals Provides Fourth Quarter 2012 Investor Update

Business Wire January 15, 2013

Ironwood Pharmaceuticals to Host Fourth Quarter 2012 Investor Update Call

Business Wire January 10, 2013

Ironwood Completes $175 Million Debt Offering

Business Wire January 4, 2013

Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

Business Wire January 2, 2013

Ironwood Begins Phase I Trial of Investigational IW-2143 Anxiety Drug in US

Troy Schwensen December 21, 2012